As of Friday close, Abbott Laboratories’s (NYSE:ABT) stock was up $1.91, moving up 1.77 percent to $109.88. The average number of shares traded per day over the past five days has been 6,807,520 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.39 fall in that time frame. In the last twenty days, the average volume was 5,743,890, while in the previous 50 days, it was 5,339,042.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, ABT stock retreated -8.03%. Shares of the company fell to $104.63 on 05/12/22, the lowest level in the past month. A 52-week high of $142.60 was reached on 01/03/22 after having rallying from a 52-week low of $104.63. Since the beginning of this year, ABT’s stock price has dropped by -21.93% or -$30.86, and marked a new high 1 time. However, the stock has declined by -22.95% since its 52-week high.
Abbott Laboratories (ABT) last reported insider trading activity 10 days ago on May 04. WOODGRIFT RANDEL WILLIAM, the SENIOR VICE PRESIDENT of the company, disposed of 24,000 shares for $113.00 on May 04. It resulted in a $2,712,103 divestment by the insider. STARKS DANIEL J sold 50,000 shares at an average price of $113.22 on May 03. The insider now owns 6,973,500 shares following the transaction. On Mar 08, SENIOR VICE PRESIDENT DALE MICHAEL D sold 4,000 shares at $117.00 apiece. The transaction was valued at $468,001.
Right now, Abbott Laboratories (ABT) has a P/E ratio of about 25.36. The stock’s beta is 0.72. Besides these, the trailing price-to-sales (P/S) ratio of 4.35, the price-to-book (PB) ratio of 5.47, and the price-to-cash flow ratio of 39.38 may also be considered.
The latest dividend of $0.47 per share was paid out, remained unchanged from last year’s $0.47. On Friday December 10 2021, a $0.02 dividend increase was announced.
In the three months ended September 29, Abbott Laboratories’s quick ratio stood at 1.40, while its current ratio was 1.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.48, and the total debt-to-equity ratio was 0.48. On the profitability front, the trailing twelve-month gross margin is 57.10% percent. In the year ended September 29, operating margins totaled 20.70%. Based on annual data, ABT earned $24.54 billion in gross profit and brought in $43.08 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.50%. Return on equity (ROE) for the past 12 months was 22.20%.
In Abbott Laboratories’s quarter-end financial report for September 29, it reported total debt of $17.09 billion against cash and short-term investments of $483.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABT’s revenue rose 12.1% to $11.47 billion during the quarter, while net income inched up to $11.89 billion. While analysts expected Abbott Laboratories to report $0.94 quarterly earnings, the actual figure was $1.4 per share, beating the consensus estimate by 48.90%. During the quarter, the company generated $3.73 billion in EBITDA. The liabilities of Abbott Laboratories were 38.38 billion at the end of its most recent quarter ended September 29, and its total debt was $18.4 billion. The value of shareholders’ equity is $1.75 billion.
This quick technical analysis looks at Abbott Laboratories’s (ABT) price momentum. With a historical volatility rate of 33.97%, the RSI 9-day stood at 41.56% on 13 May.
With respect to its five-day moving average, the current Abbott Laboratories price is down by -2.13% percent or -$2.39. At present, ABT shares trade -6.64% below its 20-day simple moving average and -18.60% percent below its 100-day simple moving average. However, the stock is currently trading approximately -9.17% below its SMA50 and -9.26% below its SMA200.
Stochastic coefficient K was 19.10% and Stochastic coefficient D was 9.91%, while ATR was 3.31. Given the Stochastic reading of 34.98% for the 14-day period, the RSI (14) reading has been calculated as 40.74%. As of today, the MACD Oscillator reading stands at -2.24, while the 14-day reading stands at -4.19.
Abbott Laboratories (ABT) has been rated Overweight by analysts. According to 1 brokerage firm, ABT is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 5 analysts rate Abbott Laboratories stock as buy, with 13 recommending it as overweight.
With a median target price of $142.00, the current consensus forecast for the stock is $115.00 – $154.00. Based on these forecasts, analysts predict Abbott Laboratories (ABT) will achieve an average price target of $141.34.